Skip to content

Study · Ex vivo tissue · 2022

5 results

New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.

Salas A, García-García P, Díaz-Rodríguez P, Évora C, Almeida TA, Delgado A

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie21 Oct 2022Cited by 5 (Europe PMC)

PMID36279721 (opens in a new tab)DOI10.1016/j.biopha.2022.113909 (opens in a new tab)PepBankPUB-36279721
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In leiomyoma explants, ganirelix-loaded PLGA microspheres induced significant death in 50-55% of tumor cells.

    In plain wordsIn leiomyoma explants, ganirelix-loaded PLGA microspheres induced significant death in 50-55% of tumor cells.

    Peptide
    Ganirelix
    Outcome
    IncreaseTumor cell death
    Study

    n: not reported in source

    Leiomyoma tissue explants
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · six daysAs given in this study.

    Source sentences

    Summary
    Microspheres maintained ganirelix concentration stably during six days of culture, inducing significant cell death in 50-55% of tumor cells.
    1 context sentence
    Summary · context
    In this study, we encapsulated the GnRH antagonist ganirelix in PLGA microspheres contained in an alginate scaffold that also supports a leiomyoma ex vivo tissue explant.
  2. 02LabEx vivo tissueMechanism

    In leiomyoma explants, ganirelix-loaded PLGA microspheres did not change extracellular matrix gene expression.

    In plain wordsIn leiomyoma explants, ganirelix-loaded PLGA microspheres did not change extracellular matrix gene expression.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedExtracellular matrix gene expression
    Study

    n: not reported in source

    Leiomyoma tissue explants
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated · six daysAs given in this study.

    Source sentences

    Summary
    Although no changes were observed in the expression of extracellular matrix genes, a decreased expression of the Nuclear Factor of Activated T cells 5, a transcription factor involved in osmotic stress and tumor size.
    1 context sentence
    Summary · context
    In this study, we encapsulated the GnRH antagonist ganirelix in PLGA microspheres contained in an alginate scaffold that also supports a leiomyoma ex vivo tissue explant.
  3. 03LabEx vivo tissueMechanism

    In leiomyoma explants, ganirelix-loaded PLGA microspheres decreased Nuclear Factor of Activated T cells 5 expression.

    In plain wordsIn leiomyoma explants, ganirelix-loaded PLGA microspheres decreased Nuclear Factor of Activated T cells 5 expression.

    Peptide
    Ganirelix
    Outcome
    DecreaseNuclear Factor of Activated T cells 5 expression
    Study

    n: not reported in source

    Leiomyoma tissue explants
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated · six daysAs given in this study.

    Source sentences

    Summary
    Although no changes were observed in the expression of extracellular matrix genes, a decreased expression of the Nuclear Factor of Activated T cells 5, a transcription factor involved in osmotic stress and tumor size.
    1 context sentence
    Summary · context
    In this study, we encapsulated the GnRH antagonist ganirelix in PLGA microspheres contained in an alginate scaffold that also supports a leiomyoma ex vivo tissue explant.
  4. 04LabEx vivo tissueMechanism

    In leiomyoma explants, all tumors exposed to ganirelix-loaded PLGA microspheres experienced apoptosis independently of the original driver mutation.

    In plain wordsIn leiomyoma explants, all tumors exposed to ganirelix-loaded PLGA microspheres experienced apoptosis independently of the original driver mutation.

    Peptide
    Ganirelix
    Outcome
    IncreaseApoptosis across driver mutations
    Study

    n: not reported in source

    Leiomyoma tissue explants
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    Dose not stated · six daysAs given in this study.

    Source sentences

    Summary
    Interestingly, all tumors analyzed experienced apoptosis independently of the original driver mutation.
    1 context sentence
    Summary · context
    In this study, we encapsulated the GnRH antagonist ganirelix in PLGA microspheres contained in an alginate scaffold that also supports a leiomyoma ex vivo tissue explant.

Studies that did not test the peptide alone1

In this study, Ganirelix was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Ganirelix.

  1. 05LabNot a test of Ganirelix aloneEx vivo tissuePharmacokinetics

    In leiomyoma explants, microspheres maintained ganirelix concentration stably during six days of culture.

    In plain wordsIn lab tests, microspheres kept ganirelix concentration stable for six days.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedSustained ganirelix concentration
    Study

    n: not reported in source

    Leiomyoma tissue explants
    Outcome group
    Pharmacokinetics · Reproductive and sexual health

    Source sentences

    Summary
    Microspheres maintained ganirelix concentration stably during six days of culture
    1 context sentence
    Summary · context
    In this study, we encapsulated the GnRH antagonist ganirelix in PLGA microspheres contained in an alginate scaffold that also supports a leiomyoma ex vivo tissue explant.

    In this study, Ganirelix was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ganirelix.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.